Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 2/20 | 0.70 |
| ▸ | EIF4E | P06730 | 5/20 | 0.62 |
| ▸ | NT5C3B | Q969T7 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31122854 | 0.98 | DCPS (0.70) | DCPSEIF4ENT5C3B | |
| SCHEMBL29466648 | 0.94 | DCPS (0.72) | DCPSEIF4ENT5C3B | |
| SCHEMBL29824509 | 0.93 | DCPS (0.72) | DCPSEIF4ENT5C3B | |
| SCHEMBL29438538 | 0.92 | DCPS (0.72) | DCPSEIF4ENT5C3B | |
| SCHEMBL29689260 | 0.87 | DCPS (0.92) | DCPS | |
| SCHEMBL29361534 | 0.83 | DCPS (0.95) | DCPSEIF4E | |
| SCHEMBL1762999 | 0.75 | P2RY2 (0.58) | DCPS | |
| SCHEMBL17586590 | 0.74 | TGM2 (0.57) | DCPS | |
| SCHEMBL20597816 | 0.74 | TGM2 (0.57) | DCPS | |
| SCHEMBL4317980 | 0.73 | DCPS (0.66) | DCPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673553-A2 | METHODS AND DEVICES FOR PREPARING CAPPED RNA BY FED-BATCH TRANSCRIPTION | Ribopro B.V. (NL) | 2026-01-07 | — | — | EP | claimed |
| US-12168003-B2 | Selective inhibition of T follicular helper cells for treatment of autoimmune disorders | NEW YORK UNIVERSITY (US) | 2024-12-17 | — | — | US | claimed |
| WO-2024180048-A2 | RNA | RIBOPRO B.V. (NL) | 2024-09-06 | — | — | WO | claimed |
| US-20230233535-A1 | SELECTIVE INHIBITION OF T FOLLICULAR HELPER CELLS FOR TREATMENT OF AUTOIMMUNE DISORDERS | UNIV NEW YORK (US) | 2023-07-27 | — | — | US | claimed |
| US-20230233592-A1 | PHARMACEUTICAL COMPOSITION FOR THE CHEMICAL INHIBITION OF TGS1 IN THE THERAPEUTIC TREATMENT OF TELOMEROPATHIES | UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA" (IT) | 2023-07-27 | — | — | US | claimed |
| EP-4157287-A1 | PHARMACEUTICAL COMPOSITION FOR THE CHEMICAL INHIBITION OF TGS1 IN THE THERAPEUTIC TREATMENT OF TELOMEROPATHIES | Università degli Studi di Roma "La Sapienza" (IT) | 2023-04-05 | — | — | EP | claimed |
| US-20220339180-A1 | Methods And Compositions For Treating Viral Diseases Using Combination Of Drugs | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2022-10-27 | — | — | US | claimed |
| EP-4069268-A1 | SELECTIVE INHIBITION OF T FOLLICULAR HELPER CELLS FOR TREATMENT OF AUTOIMMUNE DISORDERS | New York University (US) | 2022-10-12 | — | — | EP | claimed |
| US-20260144880-A1 | SMALL MOLECULE LIGAND-TARGETED DRUG CONJUGATES FOR ANTI-INFLUENZA CHEMOTHERAPY AND IMMUNOTHERAPY | PURDUE RESEARCH FOUNDATION (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260137774-A1 | Hepatitis B Virus Receptor OATP and Use Thereof | SHANGHAI HEP PHARMACEUTICAL CO LTD (CN) | 2026-05-21 | — | — | US | disclosed |
| US-20260139250-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BY TARGETING ONCOGENIC TRANSFER RNAS | THE CHILDRENS MEDICAL CENTER CORP (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4737571-A1 | VARICELLA ZOSTER VIRUS (VZV) VACCINE | Shenzhen Shenxin Biotechnology Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-4736871-A1 | RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE | Shenzhen Shenxin Biotechnology Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-4731772-A1 | CELL SPECIFIC TRANSLATION OF RNA MOLECULES | SRTD biotech GmbH (DE) | 2026-04-29 | — | — | EP | disclosed |
| WO-2022076903-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | Atea Pharmaceuticals, Inc. (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-3974520-A1 | HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS | Board of Regents, The University of Texas System (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3362461-B1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | MODERNATX INC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20220062396-A1 | HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS | UNIV TEXAS (US) | 2022-03-03 | — | — | US | disclosed |
| US-20220054606-A1 | ASPARAGINASE-INDUCED GLUTAMINE DEPLETION COMBINED WITH BCL-2 INHIBITION FOR TREATMENT OF HEMATOLOGIC AND SOLID CANCERS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3947416-A1 | PEPTIDES AND COMPOUNDS THAT BIND TO ELONGATION INITIATION FACTOR 4E | Agency for Science, Technology and Research (SG) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144880-A1 | SMALL MOLECULE LIGAND-TARGETED DRUG CONJUGATES FOR ANTI-INFLUENZA CHEMOTHERAPY AND IMMUNOTHERAPY | HAVCR2, CD4, ICOS | DCPS 4673/4885EIF4E 2083/4885NT5C3B 3715/4885 |
| US-20230233535-A1 | SELECTIVE INHIBITION OF T FOLLICULAR HELPER CELLS FOR TREATMENT OF AUTOIMMUNE DISORDERS | EIF4EBP1, EIF4E, NFATC1 | DCPS 1847/4885EIF4E 2/4885NT5C3B 391/4885 |
| US-20260139250-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BY TARGETING ONCOGENIC TRANSFER RNAS | TRDMT1, METTL16, TRMT1 | DCPS 1295/4885EIF4E 162/4885NT5C3B 371/4885 |
| US-20230233592-A1 | PHARMACEUTICAL COMPOSITION FOR THE CHEMICAL INHIBITION OF TGS1 IN THE THERAPEUTIC TREATMENT OF TELOMEROPATHIES | POT1, SPTLC1, GAR1 | DCPS 2615/4885EIF4E 2823/4885NT5C3B 3287/4885 |
| US-20260137774-A1 | Hepatitis B Virus Receptor OATP and Use Thereof | HAVCR2, SLC10A1, FABP1 | DCPS 2711/4885EIF4E 4070/4885NT5C3B 3377/4885 |
| US-12168003-B2 | Selective inhibition of T follicular helper cells for treatment of autoimmune disorders | EIF4EBP1, EIF4E, NFATC1 | DCPS 1847/4885EIF4E 2/4885NT5C3B 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.